CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade.

Abstract

It is well established that natural killer (NK) cells can be used as an alternative candidate of T cells for adoptive cell therapy (ACT) due to its high killing capacity, off-the-shelf utility, and low toxicity. Though NK cells provide rapid and potent immune effects, they still suffer from insufficient infiltration and tumor immunosuppression environment, which result in unsatisfactory therapeutic efficiency. Herein, a highly stable CD16/PD-L1 bi-specific aptamer (defined as CP-bi-apt) with high affinity and selectivity was introduced to overcome these obstacles. This CP-bi-apt can mediate a significant antitumor immunity by recruiting CD16-positive NK cells to directly contact with PD-L1 high-expressed tumor cells. In addition, the induced up-regulation of PD-L1 on tumor cells can inevitably occur as an adaptive response to most of the immunotherapeutic strategies. The prepared CP-bi-apt can be further used as an immune checkpoint inhibitor to specifically bind to PD-L1, thus reducing the negative impact of PD-L1 over-expression on the therapeutic efficacy. Furthermore, this CP-bi-apt-based immunotherapy is simple, highly efficient, and has low side effects, showing a promising potential for clinical translation.

• Authors: Aixian Zheng, Yanlin Du, Yiru Wang, Youshi Zheng, Zhaoyu Ning, Ming Wu, Cuilin Zhang, Da Zhang, Jingfeng Liu, Xiaolong Liu
• Journal: Molecular therapy. Nucleic acids (Mol Ther Nucleic Acids) Vol. 27 Pg. 998-1009 (Mar 08 2022) ISSN: 2162-2531 [Print] United States
• PMID: 35228895 (Publication Type: Journal Article)
• Copyright: © 2022 The Author(s).